These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17263652)

  • 1. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
    Gervasoni C; Vigano O; Grinelli E; Ortu M; Galli M; Rusconi S
    AIDS Patient Care STDS; 2007 Jan; 21(1):1-3. PubMed ID: 17263652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
    Moyle GJ; DeJesus E; Cahn P; Castillo SA; Zhao H; Gordon DN; Craig C; Scott TR;
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):417-25. PubMed ID: 15764958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
    Cohen CJ; Kubota M; Brachman PS; Harley WB; Schneider S; Williams VC; Sutherland-Phillips DH; Lim ML; Balu RB; Shaefer MS;
    Pharmacotherapy; 2008 Mar; 28(3):314-22. PubMed ID: 18294111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
    Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B
    Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic cough induced by abacavir apart from a context of hypersensitivity.
    Peyrière H; Mauboussin JM; Arnaud A; Rouanet I; Vincent D
    Allerg Immunol (Paris); 2002 Dec; 34(10):359-60. PubMed ID: 12575618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.